Peaccel

WHY: Making the world disease free. HOW: We find the real drug lead candidate by capturing the synergistic effect of mutations (epistasis). WHAT: We have developed the Data-Centric innov’SAR AI industrial platform for our partners. PEACCEL is definitely the ONLY company capable of fully capturing epistasis and predicting outside-the-box, we are ahead of competition especially in terms of "hit rate". We can solve the "1+1=10" challenge! The innov'SAR core approach is interpolative, extrapolative and predicts outside-of-the-box, not found in other state-of-the-art ML / DL. It can screen 1 billion mutants per day. PEACCEL can produce massive amounts of Synthetic data to train its ML/DL platform. Other companies have taken the shortcut of relying on existing datasets which are often messy and of low quality. PEACCEL is built around the 6 pillars - P6 : PLATFORM, PUBLICATIONS, PATENTS, PARTNERSHIPS, PRODUCTS and PEOPLE We have developed the innov'SAR PLATFORM, including 4 modules : 1- innov’SAR core: For the optimization of polypeptides (peptides, proteins, enzymes, antibodies, VHHs) 2- RAS module: For evaluating combination of Drugs (FDCs) in various diseases 3- automlSAR: this tool tests in parallel >135 algorithms, is agnostic with respect to the data set and can be combined with innov’SAR core & RAS module 4- GraphMut: Graph-based visualization tool of relations between the mutations of protein sequence variants and activity variations 15 PUBLICATIONS in the last 2 years Strong worldwide PATENTS (on technology using FFT), with more to come Robust PARTNERSHIPS with top notch KOLs worldwide Focus on high value PRODUCTS Highly skilled PEOPLE in high-tech fields.